Immatics Names Amie Krause Chief People Officer

Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical firm and the global leader in the precise targeting of PRAME, today disclosed the appointment of Amie Krause as its Chief People Officer (“CPO”), effective October 27, 2025. Ms. Krause brings over 20 years of expertise in fostering corporate culture, driving organizational expansion, and aligning human capital with business objectives, including within international biopharmaceutical companies. In this newly created position, her responsibilities will include overseeing Immatics’ human resources department, with a particular focus on organizational development and operations as the company advances into its commercial phase.

“As we embark on our next stage of growth, transforming into a commercial-stage enterprise, we are thrilled to welcome Amie. Her extensive background in cultivating high-performing teams and enhancing organizational effectiveness and efficiency will be instrumental in securing our continued success as we reinforce our global prominence in precision PRAME targeting,” stated Harpreet Singh, Ph.D., Chief Executive Officer and Co-Founder of Immatics. “Amie is a highly skilled leader adept at aligning people strategy with business outcomes and will be an essential asset to our leadership team as we further develop our pipeline of PRAME product candidates and prepare for the market launch of anzu-cel, our primary PRAME cell therapy candidate, aiming to offer improved treatment choices for cancer patients.”

“Immatics stands at a pivotal juncture in its mission to provide groundbreaking therapies to individuals battling cancer. I feel privileged to join at this period of significant transformation and to collaborate with such a skilled team,” commented Amie Krause, Chief People Officer of Immatics. “Leveraging Immatics’ strategic goals and varied talent pool, I am eager to cultivate an environment that promotes outstanding organizational performance and prepares us to fulfill the potential of our PRAME platform.”

Ms. Krause comes to Immatics from Dompé, where she held the position of Chief Human Resources Officer. Previously, she served as Chief People Officer at Revance Therapeutics, and before that, as Chief People Officer at Atara Biotherapeutics, a company specializing in cell therapy. Prior to her time at Atara, Amie Krause dedicated more than a decade to Amgen, where she occupied various senior HR capacities, including directing global commercial operations initiatives across the Americas, Europe, Asia, Africa, and the Middle East. Beyond her corporate career, Amie Krause is an Adjunct Professor at California Lutheran University’s School of Management and a visiting lecturer at both the University of Southern California and the University of Alabama. She earned a B.S. in business management and an MBA from California Lutheran University.

About Immatics
Immatics is dedicated to significantly improving the quality of life for cancer patients. The company is recognized as the worldwide frontrunner in the precise targeting of PRAME, an antigen present in over 50 different cancer types. Its advanced scientific research and strong clinical pipeline constitute the most extensive PRAME platform, encompassing the widest range of PRAME indications and therapeutic approaches, including TCR T-cell therapies and TCR bispecifics.

Immatics plans to utilize its corporate website as a means of releasing important non-public information. For consistent updates, connect with us on and .

Forward-Looking Statements
This press release contains certain statements that could be construed as forward-looking. Such statements typically pertain to future occurrences or the Company’s anticipated financial or operational results. Examples include declarations regarding the schedule for product candidate data read-outs, the timing, results, and structure of clinical trials (including their potential for registration-enabling status), the timeline for IND, CTA, or BLA submissions, projected market potentials for product candidates, the Company’s strategic emphasis on collaborations, and various other performance indicators. These forward-looking statements are sometimes identifiable by terms like “may,” “should,” “expect,” “plan,” “target,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential,” or “continue,” or their negative forms, variations, or comparable phrasing. However, these forward-looking statements are inherently subject to risks, uncertainties, and additional factors that could lead to actual outcomes diverging significantly from what is stated or implied. They rely on estimates and presumptions that, despite being deemed reasonable by Immatics and its leadership, carry intrinsic uncertainties. New risks and uncertainties may surface periodically, and it is impossible to foresee every single one. Elements that could cause actual results to vary substantially from present expectations encompass, though are not limited to, diverse factors outside management’s purview, such as general economic conditions and other risks, uncertainties, and considerations detailed in the Company’s Annual Report on Form 20-F and its other submissions to the Securities and Exchange Commission (SEC). No part of this press release should be interpreted as an assurance by any individual that the forward-looking statements presented herein will materialize, or that any of their projected outcomes will be attained. Readers are cautioned against placing excessive reliance on forward-looking statements, as they are valid only as of their original publication date. The Company disclaims any obligation to revise or update these forward-looking statements. All scientific and clinical data contained within this press release are, by their nature, preliminary—given they precede the finalization of the clinical trial and its official report—and remain subject to subsequent quality assurance, including standard source data verification.

To request additional details, please reach out to:

For Media Inquiries
Trophic Communications
Phone: +49 151 74416179

For Immatics N.V.
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325

– Concluded –

Attachment